Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Motor dysfunction in elderly patients with chronic musculoskeletal system diseases (locomotive syndrome)

https://doi.org/10.14412/2074-2711-2021-2-130-136

Full Text:

Abstract

 Locomotive syndrome (LS) is defined as an unsatisfactory condition in patients after the age of 60 years, in which they require or may require physical assistance soon due to deterioration in the functional state of the musculoskeletal system, including pathology of bone tissue, joints, muscles, and the nervous system. The problem of LS treatment in elderly patients is relevant for all countries over the world. The presence of chronic somatic and neurological diseases in most older adults can complicate LS assessment and reduce treatment effectiveness. The patient's functional status and ability to continue activities of daily living  should be assessed at the first visit to determine the degree of  independence, the level of need for caregivers, and the overall  quality of life. LS treatment should be permanent and include  kinesiotherapy, professional psychological support, and complex  drug therapy. The use of vital micronutrients, which include highly  purified forms of chondroitin sulfate and glucosamine sulfate,  which have a wide range of anti-inflammatory and regenerative  effects, can provide the safety of long-term drug therapy. 

About the Authors

M. V. Putilina
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

 1, Ostrovityanov St., Moscow 117997, Russia 



N. V. Teplova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

 1, Ostrovityanov St., Moscow 117997, Russia 



O. A. Gromova
Federal Research Center «Informatics and Management», Russian Academy of Sciences; Center for Big Data Storage and Analysis, National Center for Digital Economy, M.V. Lomonosov Moscow State University
Russian Federation

44, Vavilov St., Build. 2, Moscow 119333, Russia;

27, Lomonosovsky Prospect, Build. 1, Moscow 117997, Russia 



I. Yu. Torshin
Federal Research Center «Informatics and Management», Russian Academy of Sciences; Center for Big Data Storage and Analysis, National Center for Digital Economy, M.V. Lomonosov Moscow State University
Russian Federation

44, Vavilov St., Build. 2, Moscow 119333, Russia;

27, Lomonosovsky Prospect, Build. 1, Moscow 117997, Russia 



M. Yu. Maksimova
Research Center of Neurology
Russian Federation

 80, Volokolamskoe Shosse, Moscow 125367, Russia 



Yu. S. Prokofieva
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation

 20, Delegatskaya St., Moscow 127473, Russia 



References

1. World Demographic Prospects: Revised 2017 Edition Available from: https://esa.un.org/unpd/wpp/Publications/Files/WPP2017_KeyFindings.pdf (accessed 12.20.2018).

2. Putilina MV. Risk factors, features of clinical course and treatment approaches in aged patients with cerebral stroke. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = Korsakov Journal of Neurology and Psychiatry. 2011;111(5):90-5 (In Russ.).

3. Macfarlane GJ, Barnish MS, Jones GT. Persons with chronic widespread pain experience excess mortality: longitudinal results from UK Biobank and meta-analysis. Ann Rheum Dis. 2017 Nov;76(11):1815-22. doi: 10.1136/annrheumdis-2017-211476. Epub 2017 Jul 21.

4. Lee Y, Kim J, Chon D, et al. The effects of frailty and cognitive impairment on 3-year mortality in older adults. Maturitas. 2018 Jan;107:50-5. doi: 10.1016/j.maturitas.2017.10.006. Epub 2017 Oct 9.

5. Domenichiello AF, Ramsden CE. The silent epidemic of chronic pain in older adults. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:284-90. doi: 10.1016/j.pnpbp.2019.04.006. Epub 2019 Apr 17.

6. Matsumoto H, Hagino H, Wada T, Kobayashi E. Locomotive syndrome presents a risk for falls and fractures in the elderly Japanese population. Osteoporos Sarcopenia. 2016 Sep;2(3):156-63. doi: 10.1016/j.afos.2016.06.001. Epub 2016 Jul 1.

7. Ikemoto T, Arai YC. Locomotive syndrome: clinical perspectives. Clin Interv Aging. 2018 Apr 30;13:819-827. doi: 10.2147/CIA.S148683. eCollection 2018.

8. Tanimura C, Matsumoto H, Tokushima Y, et al. Self-care agency, lifestyle, and physical condition predict future frailty in communitydwelling older people. Nurs Health Sci. 2018 Mar;20(1):31-8. doi: 10.1111/nhs.12376. Epub 2017 Nov 8.

9. Castell MV, van der Pas S, Otero A, et al. Osteoarthritis and frailty in elderly individuals across six European countries: results from the European Project on OSteoArthritis (EPOSA). BMC Musculoskelet Disord. 2015 Nov 17;16:359. doi: 10.1186/s12891-015-0807-8

10. Ishak NA, Zahari Z, Justine M. Kinesiophobia, Pain, Muscle Functions, and Functional Performances among Older Persons with Low Back Pain. Pain Res Treat. 2017;2017:3489617. doi: 10.1155/2017/3489617. Epub 2017 May 29.

11. Ikemoto T, Arai YC. Locomotive syndrome: clinical perspectives. Clin Interv Aging. 2018 Apr 30;13:819-27. doi: 10.2147/CIA.S148683. eCollection 2018.

12. Putilina MV. Comorbidity in elderly patients. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(5):106-11. doi: 10.17116/jnevro201611651106-111 (In Russ.).

13. Yamada K, Kubota Y, Tabuchi T. A prospective study of knee pain, low back pain, and risk of dementia: the JAGES project. Sci Rep. 2019 Jul 23;9(1):10690. doi: 10.1038/s41598-019-47005-x

14. Veronese N, Stubbs В, Solmi М, et al. Association between lower limb osteoarthritis and incidence of depressive symptoms: data from the osteoarthritis initiative. Age Ageing. 2017 May 1;46(3):470-6. doi: 10.1093/ageing/afw216

15. Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014 Jul;73(7):1323-30. doi: 10.1136/annrheumdis-2013-204763. Epub 2014 Feb 19.

16. Zambon S, Siv'yero P, Denkinger M, et al. Role of Osteoarthritis, Comorbidity, and Pain in Determining Functional Limitations in Older Populations: European Project on Osteoarthritis. Arthritis Care Res (Hoboken). 2016 Jun;68(6):801-10. doi: 10.1002/acr.22755

17. Naumov AV, Khovasova NO, Demenok DV, et al. Age-related musculoskeletal diseases as a leading risk factor for falls. Lechebnoye delo. 2019;(1):28-39 (In Russ.).

18. Safonova YuA. Sarcopenia risk factor for falls and fractures. Klinitsist = The Clinician. 2019;13(3-4):22-8. doi: 10.17650/1818-8338-2019-13-3-4-22-28 (In Russ.).

19. Putilina MV. Osteoarthritis in the practice of a neurologist: «old-new opportunities». Supplement to the journal Consilium Medicum. 2016;(1):66-9 (In Russ.).

20. Nakamura K, Ogata T. Locomotive Syndrome: Definition and Management. Clin Rev Bone Miner Metab. 2016;14(2):56-67. doi: 10.1007/s12018-016-9208-2

21. Yoshimura N, Muraki S, Oka H, et al. Association between new indices in the locomotive syndrome risk test and decline in mobility: third survey of the ROAD study. J Orthop Sci. 2015;20(5):896-905. doi: 10.1007/s00776-015-0741-5

22. Alexandre TDS, Duarte YAO, Santos JLF, Lebrao ML. Prevalence and associated factors of sarcopenia, dynapenia, and sarcodynapenia in community-dwelling elderly in Sao Paulo – SABE Study. Revista Brasileira de Epidemiologia. 2018;21(Suppl. 2):e180009. doi: 10.1590/1980-549720180009.supl.2

23. Ethgen O, Beaudart C, Buckinx F, et al. The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. Calcif Tissue Int. 2017 Mar;100(3):229-34. doi: 10.1007/s00223-016-0220-9. Epub 2016 Dec 24.

24. Yang M, Hu X, Wang H, et al. Sarcopenia predicts readmission and mortality in elderly patients in acute care wards: a prospective study. J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):251-8. doi: 10.1002/jcsm.12163. Epub 2016 Nov 28.

25. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013 Aug;14(8):531-2. doi: 10.1016/j.jamda.2013.05.018. Epub 2013 Jun 25.

26. Livshits G, Kalinkovich A. Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Res Rev. 2019 Dec;56:100980. doi: 10.1016/j.arr.2019.100980. Epub 2019 Nov 11.

27. Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013 Jun;14(6):392-7. doi: 10.1016/j.jamda.2013.03.022

28. Lo-Ciganic WH, Floden L, Lee JK, et al. Analgesic use and risk of recurrent falls in participants with or at risk of knee osteoarthritis: data from the Osteoarthritis Initiative. Osteoarthritis Cartilage. 2017;25(9):1390-8. doi: 10.1016/j.joca.2017.03.017

29. Al-Aama T. Falls in the elderly: spectrum and prevention. Can Fam Physician. 2011 Jul;57(7):771-6. Erratum in: Can Fam Physician. 2014;60(3):225.

30. Putilina MV, Baranova OA. Results of the multicenter clinical and epidemiological observational program «GLOBUS» (determination of the prevalence of dizziness and assessment of therapy regimens

31. at the outpatient level). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(5):33-8 (In Russ.).

32. Li Y, Liu M, Sun X, et al. Independent and synergistic effects of pain, insomnia, and depression on falls among older adults: a longitudinal study. BMC Geriatr. 2020 Nov 23;20(1):491. doi: 10.1186/s12877-020-01887-z

33. Putilina MV, Soldatov MA. Cerebral strokes in old age. Features of the clinical picture, course, treatment. Vrach = Doctor. 2006;(5):29-34 (In Russ.).

34. Ali A, Arif AW, Bhan C, et al. Managing Chronic Pain in the Elderly: An Overview of the Recent Therapeutic Advancements. Cureus. 2018 Sep 13;10(9):e3293. doi: 10.7759/cureus.3293

35. Parfenov VA, Yakhno NN, Kukushkin ML. Acute non-specific (musculoskeletal) low back painGuidelines of the Russian Society for the Studyof Pain (RSSP). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):4-11. doi: 10.14412/2074-2711-2018-2-4-11 (In Russ.).

36. Lints-Martindale AC, Hadjistavropoulos T, Lix LM, Thorpe L. A comparative investigation of observational pain assessment tools for older adults with dementia. Clin J Pain. Mar-Apr 2012;28(3):226-37. doi: 10.1097/AJP.0b013e3182290d90

37. Klinicheskiye rekomendatsii po vedeniyu patsiyentov so starcheskoy asteniyey. «Rossiiyskaya assotsiatsiya gerontologov i geriatrov», 2018 [Clinical guidelines for the management of patients with senile asthenia. Russian Association of Gerontologists and Geriatricians, 2018]. Available from: http://uzrf.ru/userfiles/file/rokgvv/GeriatricCenter/01-1-astenia_recomend.pdf (In Russ.).

38. Nishimura T, Imai A, Fujimoto M, et al. Adverse effects of the coexistence of locomotive syndrome and sarcopenia on the walking ability and performance of activities of daily living in Japanese elderly females: a cross-sectional study. J Phys Ther Sci. 2020 Mar;32(3):227-32. doi: 10.1589/jpts.32.227. Epub 2020 Mar 11.

39. Putilina MV, Teplova NV. Medicinal safety as a priority area of domestic medicine. Lechebnoe delo = General Medicine. 2020;(4):7-14. doi: 10.24411/2071-5315-2019-12152 (In Russ.).

40. Putilina MV, Teplova NV. Algorithms for rational pharmacotherapy of chronic cerebral ischemia. Nervnye bolezni = Nervous Diseases. 2019;(1):11-16. doi: 10.24411/2071-5315-2018-12074 (In Russ.).

41. Wanigatunga AA, Di J, Zipunnikov V, et al. Association of total daily physical activity and fragmented physical activity with mortality in older adults. JAMA Netw Open. 2019 Oct 2;2(10):e1912352. doi: 10.1001/jamanetworkopen.2019.12352

42. Verlaan S, Maier AB, Bauer JM, et al. Sufficient levels of 25-hydroxyvitamin D and protein intake required to increase muscle mass in sarcopenic older adults. The PROVIDE study. Clin Nutr. 2018 Apr;37(2):551-7. doi: 10.1016/j.clnu.2017.01.005. Epub 2017 Jan 17.

43. Gromova OA, Torshin IYu, Lila AM, et al. Molecular mechanisms of myoprotective action of chondroitin sulfate and glucosamine sulfate in sarcopenia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):117-24. doi: 10.14412/2074-2711-2019-1-117-124 (In Russ.).

44. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-89. doi: 10.1016/j.joca.2019.06.011. Epub 2019 Jul 3.

45. Bell GA, Kantor ED, Lampe JW, et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012 Aug;27(8):593-603. doi: 10.1007/s10654-012-9714-6. Epub 2012 Jul 25.

46. Putilina MV. Aging as a degenerative process. Safe strategies for dementia treatment in elderly patients. Consilium Medicum. 2018;20(2):24-9. doi: 10.26442/2075-1753_2018.2.24-29 (In Russ.).

47. Honvo G, Bruyere O, Geerinck A, et al. Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. Adv Ther. 2019 May;36(5):1085-99. doi: 10.1007/s12325-019-00921-w. Epub 2019 Mar 16.

48. Railhac JJ, Zaim M, Saurel AS, et al. Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo- controlled pilot study using MRI. Clin Rheumatol. 2012 Sep;31(9):1347-57. doi: 10.1007/s10067-012-2022-4. Epub 2012 Jun 23.

49. Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci. 2007 Dec;96(12):3168-80. doi: 10.1002/jps.20997

50. Sharapova EP, Kashevarova NG, Taskina EA, et al. Study of the efficacy, tolerability and safety of the drug Chondrogard in patients with osteoarthritis of the knee joints and comorbidity. Farmateka 2017;(7):46-51 (In Russ.).

51. Udovika MI. Comparative efficacy of injectable and oral symptomatic slow action drugs in the therapy of primary and posttraumatic osteoarthritis of the knee joints. RMJ. 2017;(4):446-50 (In Russ.).

52. Torshin IYu, Lila AM, Naumov AV, et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Pharmacoeconomic. Modern Pharmacoeconomic and Pharmacoepidemiology. 2020;13(4):388-99. doi: 0.17749/2070-4909/farmakoekonomika.2020.066 (In Russ.).

53. Naumov AV, Sharov MN, Khovasova NO, Prokof'yeva YuS. The results of the use of the intermittent scheme of parenteral administration of chondroitin sulfate and glucosamine sulfate in the initial therapy of chronic pain in joints and back in comorbid patients. RMJ. 2018;4(2):47-54 (In Russ.).


For citation:


Putilina M.V., Teplova N.V., Gromova O.A., Torshin I.Yu., Maksimova M.Yu., Prokofieva Yu.S. Motor dysfunction in elderly patients with chronic musculoskeletal system diseases (locomotive syndrome). Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):130-136. (In Russ.) https://doi.org/10.14412/2074-2711-2021-2-130-136

Views: 33


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)